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Abstract 
The majority of asthma exacerbations are caused by rhinovirus. Currently the 
treatment of asthma exacerbations is inadequate. Previous evidence suggests that 
macrolide antibiotics have anti-inflammatory and anti-viral effects however the 
mechanism is unknown. We investigated the anti-rhinoviral potential of macrolides 
through the induction of anti-viral gene mRNA and protein. Primary human bronchial 
epithelial cells were pre-treated with the macrolides Azithromycin, Erythromycin and 
Telithromycin, and infected with minor group rhinovirus 1B and major group 
rhinovirus 16. The mRNA expression of the anti-viral genes, type I interferon-β and 
type III interferon-λ1, interferon-λ2/3, and interferon stimulated genes (retinoic acid 
inducible gene I, melanoma differentiation associated gene 5, oligoadenylate 
synthase, MxA and Viperin) and pro-inflammatory cytokines (IL-6 and IL-8), and 
rhinovirus replication and release were measured. Azithromycin, but not 
Erythromycin or Telithromycin significantly increased rhinovirus 1B and 16 induced 
interferons and interferon stimulated gene mRNA expression and protein production. 
Furthermore, Azithromycin significantly reduced rhinovirus replication and release. 
Rhinovirus induced IL-6 and IL-8 protein and mRNA expression were not 
significantly reduced by Azithromycin pre-treatment. In conclusion, the results 
demonstrate that Azithromycin has anti-rhinoviral activity in bronchial epithelial 
cells, and during rhinovirus infection increases the production of interferon stimulated 
genes. 
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Introduction 
 
Respiratory viral infections are associated with the majority of asthma exacerbations 
(approximately 80%) in both adults [1,2] and children [3,4]. Asthma exacerbations are 
the major cause of morbidity, mortality and healthcare costs in asthma [5]. The 
mechanisms of virus induced asthma exacerbations are poorly understood [6]. Inhaled 
corticosteroids reduce asthma exacerbation frequency [7-9]; however, this effect is 
only partial even in combination with long-acting β2-agonists [10,11], more effective 
therapies are therefore necessary. Rhinoviruses (RV) are responsible for 
approximately 60% of virus induced exacerbations [1,4]. Asthmatics have an 
increased susceptibility to RV infection compared to normal subjects [1]. A novel 
mechanism for this increased susceptibility has been identified recently: asthmatics 
exhibit lower levels of interferon (IFN)-β and IFN-λ gene and protein expression upon 
RV infection [12,13], and IFN-λ levels negatively correlate with exacerbation severity 
[13].  
 
Type I IFNs consist of the single gene IFN-β and numerous IFN-αs. The recently 
discovered type III IFNs consist of IFN-λ1,2,3 (respectively IL-29, IL-28A and IL-
28B). The major IFNs produced by bronchial epithelial cells are IFN-β and- λ [14]. 
Despite using different receptor complexes, both types of IFNs have functional 
similarities, including antiviral effects through stimulation of the innate and adaptive 
immune responses. After secretion, IFNs bind to the surface of infected and 
neighbouring cells to initiate the Janus activated kinases (JAKs) and the signal 
transducers and activators of transcription (STATs). Activation of the JAK-STAT 
pathway leads to the induction of many interferon stimulated genes (ISGs), which 
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prevent viral replication such as MxA [15], Viperin [16] or the 2’-5’ oligoadenylate 
synthesase (OAS) family [17], and also recognise viral RNA, such as retinoic acid 
inducible gene I (RIG-I) [18], and melanoma differentiation associated gene 5 
(MDA5) [19]. As asthmatics have defective IFN-β and IFN-λ expression, one 
potential approach to therapy of asthma exacerbations is to augment host IFN 
responses and induction of anti-viral ISG expression. 
 
Macrolides include Erythromycin (EM), Azithromycin (AM) and the ketomacrolide 
Telithromycin (Tel). They have well established anti-bacterial [20] and anti-
inflammatory effects [21-23], and preliminary evidence showed that they may also 
have anti-viral effects [24-27]. The anti-bacterial action of macrolides is through 
inhibition of protein synthesis via binding to the 50S subunit of bacterial ribosomes. 
Macrolides also inhibit IL-6 and IL-8 protein production and reduce neutrophil 
attraction to the site of infection, likely through inhibiting NF-κB [21,28]. Tel was 
reported to have a beneficial effect in treatment of asthma exacerbations, with Tel 
treated patients experiencing greater improvements in lower airway symptoms and 
lung function compared to placebo treated patients though the mechanisms of this 
therapeutic effect are unknown [29]. In vitro studies report an anti-rhinoviral and anti-
inflammatory effect of some macrolide antibiotics [24,26,27], possibly via a reduction 
of ICAM-1 mRNA expression after major group RV infection, which use ICAM-1 as 
their receptor. In contrast,  anti-viral effects were also observed for minor group RVs, 
which utilise a different receptor [26,27]. The mechanisms for this effect are therefore 
unknown. 
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We hypothesised that the beneficial effects of macrolide antibiotics in asthma 
exacerbations may be due, at least in part, to their ability to exhibit anti-viral activity. 
In the current study, we used in vitro models of normal primary human bronchial 
epithelial cell (HBEC) culture and investigated the effects of the macrolides AM, EM 
and Tel on IFN and ISG gene expression, ISG protein induction and also the anti-viral 
activity during RV infection. 
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Materials and Methods 
Cell and virus culture  
Human bronchial epithelial cells (HBEC, Lonza, Cleveland, USA) were cultured in 
BEGM according to manufacturers recommendations. RV1B and RV16 (ATCC, 
Rockville, USA) were prepared as previously described [30], and were titrated on 
HeLa cells to ascertain their 50% tissue culture infective dose (TCID50)/mL [31]. The 
identity of each virus was confirmed by inhibition with serotype specific antibody 
using titration assays. Both viruses were negative for Mycoplasma infection. 
 
Treatment with macrolides and infection of HBECs with RV1B 
HBEC cells were cultured in 12-well tissue culture plates (Nunc, Rochester, NY) until 
80-90% confluent before being treated with AM, EM (Sigma-Aldrich, St Louis MA),  
and Tel (a kind gift from Sanofi Aventis) at a concentration of 10μM or 50μM in 
bronchial epithelial basal medium (BEBM) for 24h. The diluent used for all three 
macrolides was 96% ethanol, at a final concentration of 0.05% for 50μM macrolides 
and was confirmed in preliminary experiments not to have any effect on measured 
outcomes (data not shown). HBECs were then infected with RV1B, at multiplicity of 
infection (MOI) 1 or 0.25, or RV16 (MOI of 1) for 1h with shaking at room 
temperature and replaced with 1mL of BEBM. After 8, 24 and 48h, supernatants and 
cells were harvested in RLT-buffer (Qiagen, Crawley, UK) for RNA isolation, or in 
2% Tris-glycine SDS sample buffer (Invitrogen, Paisley, UK) for protein. 
Supernatants and lysates were stored at -80°C until analysis. 
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RNA isolation and cDNA synthesis 
Total RNA isolation was performed using RNeasy® mini kit (Qiagen) according to 
the manufacturers’ recommendations. cDNA was prepared using random primers 
(Promega, Maddison, WI) and Omniscript RT kit (Qiagen) according to 
manufacturers recommendations and stored at -80˚C. 
 
TaqMan real time PCR 
In a 25μL PCR reaction, 2μL cDNA was amplified in a 7500 Sequence Detector, 
using the 2x QuantiTect Probe PCR Master Mix (Qiagen), 50nM forward primer and 
300nM reverse primer and 100nM probe were used for RV, 300nM primers and 
100nM probe were used for the 18S rRNA internal control, 300nM forward primer, 
900nM reverse primer and 100nM probe for OAS, IL-29 and IFN-β and 900nM 
primers and 100nM probes for MxA, Viperin, IL-28, IL-6, IL-8, RIG-I and MDA5 
(all FAM-TAMRA labelled). Sequences of primers and probes used are listed in 
Table 1. The copy numbers were determined via standard curves of each gene 
constructed as dsDNA plasmids, and normalised with the housekeeping gene 18S 
rRNA. Data is presented as % of copy number of control wells (RV1B), from 
approximately 2.5x105 cells/well. 
 
ELISA 
IL-6 and IL-8 were quantified by ELISA using commercially available paired 
antibodies and standards, following the manufacturer’s instructions (R&D Systems, 
Abingdon, UK). The sensitivity of each assay was 10pg/mL. 
 
SDS PAGE and Western Blotting  
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Total protein lysates were run on 4-12% Bis-Tris polyacrylamide gels, and transferred 
onto nitrocellulose membranes (Invitrogen), blocked in 5% skimmed milk, and 
probed with antibodies specific for human RIG-I 0.083µg/mL (Cell Signalling, 
Danvers, MA, USA), RSAD2/Viperin 0.3µg/mL (ProteinTech Group, Chicago, 
USA), OAS1 0.5µg/mL (Abgent, San Diego, USA), MxA 0.2µg/mL (Santa Cruz 
Biotechnology Inc) or α-tubulin 0.2µg/mL (Santa Cruz Biotechnology Inc). 
Secondary antibodies used were goat anti-mouse HRP, 0.08µg/mL and sheep anti-
rabbit HRP, 2µg/mL (AbD Serotec, Oxford, UK). Blots were developed using ECL 
(GE Healthcare, Chalfont St Giles, UK).  
 
Virus titration assay 
Supernatants were serially diluted in DMEM containing 4% FCS (Invitrogen) and 
titrated on HeLa cells to determine the TCID50/mL of the RV in the supernatants 
(42). Each dilution was assayed in eight replicates, and TCID50/mL was calculated 
according to the Spearman-Karber formula [31]. 
 
Statistical analysis 
All data were expressed as means±SEM. Comparisons of different groups were 
analyzed using one-way analysis of variance (ANOVA) with Bonferroni post testing 
(Prism, GraphPad Software, San Diego, CA). Values were considered significant if 
p<0.05. All experimental work was performed as 3-5 independent experiments.  
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Results 
RV1B increases type I and III IFN and ISG mRNA expression 
At 8h after infection, RV1B (MOI 0.25) significantly induced IL-28 mRNA 
expression (p<0.01, data not shown) and at MOI 1 there was a significant induction of 
IL-28, MxA, RIG-I, MDA-5 (p<0.05) and OAS (p<0.01) compared to medium treated 
cells (data not shown). At 24h after infection, RV1B significantly induced type I and 
III IFNs and the ISGs measured at both RV1B concentrations compared to medium 
treated cells. RV1B increased IFN-β mRNA levels from 8.9x103 (±4.4x103) copy 
number per 2.5x105 cells to 1.6x105 (±6.2x104, p<0.05) at MOI 0.25 and to 5.6x105 
(±2.1x105, p<0.05) at MOI 1, IL-28 from 1.3x101 (±1.1x101) to 1.1x105 (±4.3x104, 
p<0.05) at MOI 0.25 and to 5.6x105  (±3.0x105, p<0.05) at MOI 1 and IL-29 mRNA 
from 1.6x101 (±0.6x100) to 3.2x103 (±6.9x102, p<0.05) at MOI 0.25 and to 5.2x106 
(±3.3x104, p<0.05) at MOI 1 24h post infection. ISG mRNA levels were also 
significantly increased by RV1B 24h post infection, Viperin was increased from 
2.5x101 (±2.3x101) copy number per 2.5x105 cells to 9.2x105 (±4.4x105, p<0.05) at 
MOI 0.25 and to 1.2x106 (±3.9x105, p<0.05) at MOI 1, MxA from 1.1x104 (±1.4x103) 
to 3.5x106 (±1.4x106, p<0.05) at MOI 0.25 and to 3.7x106 (±1.3x106, p<0.05) at MOI 
1, OAS from 1.8x105 (±4.4x104) to 4.3x106 (±1.3x106, p<0.01) at MOI 0.25 and 
4.0x106 (±1.2x106, p<0.01) at MOI 1, RIG-I from 2.0x105 (±4.7x104) to 1.5x106 
(±4.7x105, p<0.05) at MOI 0.25 and 3.2x106 (±1.1x106, p<0.05) at MOI 1 and MDA5 
from 3.2 x104 (±6.7 x103) to 2.5x105 (±8.0x104, p<0.05) at MOI 0.25 and 2.8x105 
(±6.8x104, p<0.01) at MOI 1.  
 
AM increases RV1B induced type I and type III IFN mRNA expression 
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RV1B (MOI 1 and 0.25, Fig. 1) induced type I and III IFN and the effects of AM, EM 
and Tel pre-treatment on this were determined using real-time PCR. RV1B infection 
(MOI 1 and 0.25, respectively Fig. 1A,B,C and Fig. 1D,E,F) increased type I and III 
IFN mRNA expression in HBECs 24h post infection. RV1B (MOI 1) induced IFN-β 
(Fig.1A), IL-28 (Fig.1B) and IL-29 (Fig.1C) mRNA expression was non-significantly 
increased by 10μM and 50μM AM compared to RV1B infected cells. RV1B (MOI 
0.25) induced IFN-β (Fig.1D), IL-28 (Fig.1E) and IL-29 (Fig.1F) mRNA expression 
and this was non-significantly increased at 10μM AM and significantly increased at 
50μM AM (p<0.05) compared to control (RV1B infected cells). The effects of EM 
and Tel on RV induced type I and III IFN mRNA expression were also investigated, 
but neither macrolide had any significant effect on RV1B induced IFN or ISGs (data 
not shown). 
 
AM increases RV1B induced ISG mRNA and protein expression 
RV1B (MOI 1 and 0.25, respectively Fig. 2 and Fig. 3) induced ISG mRNA and the 
effects of AM, EM and Tel pre-treatment on this were determined using real-time 
PCR. RV1B (MOI 1) induced ISG mRNA expression was increased by AM at 10μM 
and 50μM at 24h post infection, RIG-I (Fig.2A), OAS (Fig.2C), Viperin (Fig.2D) and 
MxA (Fig.2E) mRNA expression were non-significantly increased by 10μM and 
significantly increased at 50μM AM (respectively p<0.01, p<0.001, p<0.01 and 
p<0.05) compared to control (RV1B MOI 1). MDA5 mRNA expression was non-
significantly increased at 10μM and 50μM AM compared to control (RV1B MOI 1, 
Fig.2B). To confirm the effects of AM on ISG mRNA, using western blotting, RV1B 
(MOI 1, Fig. 4) induced ISG protein and the effects of AM on this were determined. 
RV1B induced Viperin, RIG-I, OAS and MxA protein were further increased by AM 
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in a dose dependent manner.  AM did not induce any of these ISGs when 
administered alone (Fig. 2F).The cytoskeletal protein α-tubulin was used as load 
control. RV1B (MOI 0.25), induced ISG mRNA expression was increased by AM at 
10μM and 50μM at 24h post infection, RIG-I (Fig.3A), OAS (Fig.3C), Viperin 
(Fig.3D) and MxA (Fig.3E) mRNA expression were non-significantly increased by 
10μM and significantly increased at 50μM AM (p<0.01, p<0.001 and p<0.01 
respectively) compared to control (RV1B MOI 0.25). MDA5 mRNA expression was 
non-significantly increased at 10μM AM and 50μM AM compared to control (RV1B, 
Fig.3B). The effects of EM and Tel on RV induced ISG mRNA expression were also 
investigated, but neither macrolide had any significant effect (data not shown).  
 
AM increases RV16 induced ISG mRNA and protein expression 
HBECs were also infected with major group RV16 following pre-treatment with AM. 
Fig 4 shows that RV16 induced IFN-β (Fig 4A), MxA (Fig 4B) and Viperin (Fig 4C) 
was enhanced by 10μM AM and significantly augmented with 50μM AM (p<0.05, 
p<0.05, p<0.01 versus RV16 control, respectively). To confirm the effects of AM on 
ISG induction, RV16 induced ISG protein by western blot and the effects of AM on 
this were determined. RV16 induced Viperin, and MxA protein were further increased 
by AM in a dose dependent manner. AM did not induce any of these ISGs when 
administered alone. The cytoskeletal protein α-tubulin was used as load control.  (Fig. 
4D). 
 
AM has no significant effects on RV1B induced pro-inflammatory cytokines  
The effects of AM, EM and Tel on RV1B induced IL-6 and IL-8 mRNA levels were 
determined by real-time PCR and RV1B induced IL-8 and IL-6 protein levels 
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determined by ELISA (Fig.5) AM reduced  IL-6 and IL-8 mRNA expression and 
protein levels modestly, but not statistically significant at either concentration at 24h 
post infection (Fig.5). The effects of EM and Tel on RV1B induced IL-8 and IL-6 
mRNA were also investigated, but both macrolides did not have any significant effect 
(data not shown). 
 
AM suppresses RV replication and release 
The effects of AM, EM and Tel on RV1B and RV16 release and RNA was measured 
using a virus titration assay and quantitative PCR for viral RNA. RV1B RNA (Fig. 
6A) at 24h and 48h post infection was non-significantly reduced by 10μM AM and 
significantly reduced by 50μM AM (p<0.001). At 48h post infection 10μM AM also 
significant reduced RV1B RNA abundance (p<0.001). Furthermore, the reduction by 
50μM AM was significantly more than by 10μM AM (p<0.001).RV1B release (Fig. 
6B) was significantly reduced by 50μM AM at 24h (p<0.05) and 48h (p<0.001). AM 
at 10μM had no significant effect on RV1B release. RV16 RNA abundance was 
significantly decreased by 50 μM AM at 24h (p<0.01, Fig 6C). RV16 RNA at 48h 
was also decreased by AM, significantly so 50μM AM (p<0.001, Fig 6C). RV16 
release was not affected at 24h post infection however was significantly affected 
using AM at 50μM (p<0.05, Fig 6D). The effects of EM and Tel on RV1B release and 
replication were also investigated, but both macrolides did not have any significant 
effect on RV replication (data not shown). 
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Discussion 
The current treatment of asthma consists of corticosteroids and/or β2-agonists, and 
only partially prevents asthma exacerbations. A vital need exists for new treatment 
regimes for this form of asthma. Macrolide antibiotics have anti-inflammatory activity 
and possibly anti-viral activity in airway epithelial cell lines [24,26,27], although the 
exact a mechanism of this is unclear. In our study, AM, but not EM and Tel, increased 
RV induced IFN and ISG responses and reduced RV replication and release in 
HBECs. The macrolides had no anti-inflammatory effect.   
 
Several macrolide antibiotics have anti-inflammatory effects, demonstrated by 
inhibition of the production of pro-inflammatory cytokines in vitro [22,24-28,32]. 
This effects occurs via suppression of NF-κB activation in human bronchial epithelial 
cells [22,24,32]. Reduction of cytokines such as IL-6 and IL-8 can be an 
advantageous mechanism that leads to attenuation of airway inflammation. Other 
studies have reported anti-inflammatory activity of Clarithromycin, Bafilomycin A1 
and EM on major group RV infection, and minor group RV infection for EM, in 
airway epithelial cells showing reduction of RV induced pro-inflammatory cytokines 
[24,26,27]. In the present study we showed no significant reduction of RV1B induced 
IL-6 and IL-8 mRNA and protein by AM, EM or Tel. This data questions the anti-
inflammatory potential of macrolides and the mechanism of this in bronchial 
epithelial cells.  
 
The conflicting results observed in studies with various macrolides may be explained 
by differences in experimental model. In the present study, using primary bronchial 
epithelial cells, we used shorter incubation times with the macrolides and sampled at 
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24 to 48h post RV infection, as primary bronchial epithelial cells are more susceptible 
to RV infection than cell lines, requiring a shorter duration of experimentation. The 
reduction of RV induced anti-inflammatory cytokines previously observed by 
macrolides is also modest, at best. The reduction of pro-inflammatory molecules by 
macrolides in micromolar concentrations range from 80-25% [24,26,27]. In contrast, 
corticosteroids reduce RV induced pro-inflammatory cytokine production by 70-85% 
in bronchial epithelial cells using nanomolar concentrations [33]. Therefore the anti-
inflammatory effects observed with macrolides are modest if compared to the anti-
inflammatory effects of corticosteroids, and require much higher doses, questioning 
their real use as anti-inflammatory agents. 
 
A possible mechanism of anti-RV activity of macrolides has been demonstrated as 
reduction of ICAM-1, the receptor of major group RVs. However the anti-rhinoviral 
effects of macrolides can not be completely explained by this. A range of studies have 
suggested that macrolides inhibit replication of both major and minor groups of RV 
[24,26,27]. Furthermore, a study by Suzuki et al observed anti-viral effects of EM on 
minor group RV2, but no reduction in the LDL receptor, the receptor for minor group 
RV [27]. Our study further supports that the anti-viral effects of macrolides are not 
completely dependent on reduction of ICAM-1, as our results show suppression of 
viral replication with minor group RV1B and major group RV16, which therefore can 
not be explained by reduction of the major group RV receptor, ICAM-1. 
 
In our studies, AM reduced RV1B and RV16 replication and release into 
supernatants, and increased ISG gene and protein expression. The ISGs studied have 
been shown to have anti-viral activity. Recently Viperin, one of the RV induced ISGs 
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increased by AM, is required for the host defence against RV infection in human 
bronchial epithelial cells [34]. The anti-viral role for the other ISGs investigated in the 
present study have not been yet established to have rhinoviral activity in bronchial 
epithelial cells, yet are well established in other viral infections [35,36].  
 
AM also induced the mRNA and protein of the important intracellular dsRNA and 
ssRNA pattern recognition molecules RIG-I and MDA5, required for IFN-β induction  
[18]. Hence not only are macrolides responsible for direct induction of anti-viral 
genes, but they also upregulate the sensors of viral infection. This may be desirable 
for use as a therapeutic treatment given shortly after viral infection, whereby 
macrolides if given topically to the airway, during viral infection, could potentially 
increase the number of sensory molecules ready to detect and respond to replicating 
viral nucleic acid. 
 
We found that the macrolides did not induce anti-viral genes by themselves. Currently 
we do not understand the mechanism of how AM induces anti-viral activity in the 
presence of RV infection. Anti-viral ISGs can be induced via IRF transcription factors 
following virus infection [37]. One possible mechanism of AM could be activation of 
signalling pathways including IκB-kinase (IKK)-β [38], IKK-ι/ε [37] and TBK-1 [39], 
producing IRF activation. Alternatively, macrolides may act via the type I IFN 
receptor complex (IFNAR1), inducing IRF9, IRF7 and STAT1/2, producing the 
transcription factor ISGF3 [40,41]. AM could in theory act on the IFNAR1 complex, 
or the receptor complex for IL-29 and IL-28 [42].  
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In vivo studies of macrolides have shown contradictory results. Clarythromycin had 
no effect on the development of cold symptoms and nasal inflammation  In contrast, 
the TELICAST study demonstrated the potential benefits of the macrolide antibiotic 
Tel in the treatment of asthma exacerbations [29]. Whether the success of the 
TELICAST study was in part due to anti-viral activity is unknown. Interestingly, we 
found no anti-viral activity of Tel in vitro, suggesting that the positive effect of Tel in 
asthma exacerbations is either unrelated to virus infection or through anti-viral 
properties in other cell types and different immune responses during infection. This 
data demonstrates that although studies in cell lines are important and useful in 
defining mechanisms, results need to be confirmed in vivo. A similar study examining 
the effects of AM as a treatment for asthma exacerbations would therefore be 
appealing.  
 
In summary, we present a possible new mechanism of anti-rhinoviral activity of 
macrolides in human bronchial epithelial cells. This is the first study showing anti-
viral effects of macrolides in primary human bronchial epithelial cells, which is the 
site of infection of RV in vivo and therefore important in rhinovirus induced asthma 
exacerbations [43,44]. While only modest, the upregulation of IFNs and ISGs and 
suppression of RV replication may have consequences on asthma exacerbations and 
may further explain the anti-viral effects seen in previous studies. The importance and 
protective role of IFN-β and IFN-λ in asthma exacerbations have recently been shown 
[12,13], and epidemiological studies have provided a model of the disease burden 
associated with RV induced asthma exacerbations. Whether the anti-viral effects of 
AM can be used as a therapeutic treatment for asthma exacerbations requires further 
study in appropriate animal and human models. 
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Table 1: Primer and probe sequences 5’-3’ 
 
Gene Forward primer Reverse primer 
 
Probe 
(5’-FAM, 3’-TAMRA) 
18s rRNA CGCCGCTAGAGGTGA
AATTCT 
CATTCTTGGCAAATG
CTTTCG 
ACCGGCGCAAGACG
GACCAGA 
IFN-β CACGGATACAGAACC
TATGG 
ACGAACAGTGTCGCC
TACTA 
TCAGACAAGATTCAT
CTAGCACTGGCTGGA 
IL-28 CTGCCACATAGCCCA
GTTCA 
AGAAGCGACTCTTCT
AAGGCATCTT 
TCTCCACAGGAGCTG
CAGGCCTTTA 
IL-29 GGACGCCTTGGAAGA
GTCACT 
AGAAGCCTCAGGTCC
CAATTC 
AGTTGCAGCTCTCCT
GTCTTCCCCG 
RIG-I CCAAGCCAAAGCAGT
TTTCAA 
CACARGGATTCCCCA
GTCATG 
TTGAAAAAAGAGCA
AAGATATTCTGTGCC
CGAC 
MDA-5 GATTCAGGCACCATG
GGAAGT 
AGGCCTGAGCTGGAG
TTCTG 
GGGATGCTCTTGCTG 
CCA CAT TCT CTT 
OAS CTGACFCTGACCTGG
TTGTCT 
CCCCGGCGATTTAAC
TGAT 
CCTCAGTCCTCTCAC
CACTTTTCA 
MXA CAGCACCTGATGGCC
TATCAC 
CATGAACTGGATGAT
CAAAGG 
AGGCCAGCAAGCGC
ATCTCCAG 
Viperin CACAAAGAAGTGTCC
TGCTTGGT 
AAGCGCATATATTTC
ATCCAGAATAAG 
CCTGAATCTAACCAG
AAGATGAAAGACTCC 
IL-6 CCAGGAGCCCAGCTA 
TGA AC 
CCCAGGGAGAAGGC
A ACTG 
CCTTCTCCACAAGCG 
CCTTCGGT 
IL-8 CTGGCCGTGGCTCTC
TTG 
CCTTGGCAAAACTGC
ACCTT 
CAGCCTTCCTGATTT
CTGCAGCTCTGTGT 
RV GTGAAGAGCCSCRTG
TGCT 
GCTSCAGGGTTAAGG
TTAGCC 
TGAGTCCTCCGGCCC
CTGAATG 
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Figure Legends 
Figure 1: AM increased minor group RV1B induced IFN gene expression.  
 
HBECs were pre-treated with AM or medium for 24h and infected with RV1B MOI 1 
(A,B.C) or MOI 0.25 (D,E,F), or treated with medium. AM and RV1B induced mRNA 
levels of IFN-β (A,D), IL-28 (B,E) and IL-29 (C,F), measured by real time PCR at 24h 
post infection compared to control (RV1B infected cells, n=5). 
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Figure 2: AM increased high dose RV1B induced ISGs.  
 
HBECs were pre-treated with AM or medium for 24h and infected with RV1B MOI 1 
or treated with medium. AM and RV1B induced mRNA levels of RIG-I (A), MDA5 
(B), OAS (C), Viperin (D) and MxA (E), measured by real time PCR at 24h post 
infection compared to control (RV1B infected cells, n=5). Both 10 and 50μM AM 
increased RV1B induced ISG protein in HBECs compared with RV1B infected cells 
(the above figure is representative of 3 independent experiments, F). 
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Figure 3: AM increased low dose RV1B induced ISGs.  
 
HBECs were pre-treated with AM or medium for 24h and infected with RV1B MOI 
0.25 or treated with medium. AM and RV1B induced mRNA levels of RIG-I (A), 
MDA5 (B), OAS (C), Viperin (D) and MxA (E), measured by real time PCR at 24h 
post infection (n=5).  
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Figure 4: AM increased major group RV16 induced ISGs  
 
AM HBECs were pre-treated with AM or medium for 24h and infected with RV16 
MOI 1 or treated with medium. AM and RV1B induced mRNA levels of IFN-β (A), 
MxA (B) and Viperin (C) measured by real time PCR at 24h post infection (n=5). 
Both 10 and 50μM AM increased RV16 induced ISG protein in HBECs compared 
with RV16 infected cells (the above figure is representative of 3 experiments, F). 
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Figure 5: AM had no effect on RV induced pro-inflammatory cytokines.  
 
HBECs were pre-treated with AM or medium for 24h and infected with RV1B MOI 1 
or treated with medium. AM and RV1B at either 10 or 50μM did not significantly 
increase RV1B induced IL-8 mRNA (A), IL-6 mRNA (B), as measured by real time 
PCR at 24h post infection or IL-8 protein (C) or IL-6 protein (D) as measured by 
ELISA at 24h post infection compared to control (RV1B infected cells, n=5). 
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Figure 6: AM reduced RV1B and RV16 replication.  
 
HBECs were pre-treated with AM or medium for 24h and infected with RV1B or 
RV16 MOI 1. At 50μM, AM decreased RV1B RNA at 24h, and also at 10 and 50μM 
at 48h post infection, as assessed by real time PCR (A). AM at 50μM reduced RV1B 
release at 24h and 48h (B) (n=8). At 50μM, AM decreased RV16 RNA at 24h, and 
also at 50μM at 48h post infection, as assessed by real time PCR (C). AM at 50μM 
reduced RV16 release at 48h (D, n=5).  
 
 
 
 
